Insmed (NASDAQ:INSM) CEO Sells $1,746,290.78 in Stock

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the firm's stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $163.22, for a total value of $1,746,290.78. Following the completion of the sale, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $49,159,415.70. This represents a 3.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

• Russell Rebalance: 3 Stocks Ready to Move Higher

William Lewis also recently made the following trade(s):

• On Thursday, March 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $143.52, for a total value of $1,535,520.48.
• On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $146.03, for a total value of $1,562,374.97.
• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $150.97, for a total value of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The shares were sold at an average price of $147.79, for a total value of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The shares were sold at an average price of $156.34, for a total value of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The shares were sold at an average price of $158.93, for a total value of $1,700,392.07.
• On Monday, January 12th, William Lewis sold 19,215 shares of Insmed stock. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00.
• On Thursday, January 8th, William Lewis sold 3,223 shares of Insmed stock. The shares were sold at an average price of $174.17, for a total value of $561,349.91.

Insmed Trading Down 1.7%

---

---

Shares of NASDAQ:INSM opened at $160.18 on Thursday. The company has a market cap of $34.57 billion, a P/E ratio of -24.99 and a beta of 1.10. The stock's 50-day moving average is $150.48 and its 200-day moving average is $167.03. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83.

• Stock Rotation is Underway: Here are the Winners Moving Forward

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. During the same period last year, the business earned ($1.32) earnings per share. The firm's quarterly revenue was up 152.6% compared to the same quarter last year. Equities research analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Neutral Sentiment: CEO William Lewis sold 10,699 shares under a pre-arranged Rule 10b5-1 plan (3.43% reduction of his holding); sale reduces optics concerns tied to insider selling but is pre-planned. InsiderTrades: William Lewis sale
• Neutral Sentiment: Billionaire investor Stan Druckenmiller has trimmed a stake in INSM in the past (portfolio activity noted by media); a trim from a prominent holder can be viewed as neutral-to-slightly bearish signal depending on size. InsiderMonkey: Druckenmiller trims stake
• Neutral Sentiment: Insmed emphasized the CEDAR study showed no new safety signals for either dose of brensocatib, which limits downside from safety surprises but doesn’t salvage efficacy failure. PR Newswire: Clinical update
• Negative Sentiment: Insmed will discontinue its brensocatib (Brinsupri) HS program after the Phase 2b CEDAR trial failed to meet primary and secondary endpoints — placebo performed better; loss of this indication reduces future revenue potential and pipeline optionality, pressuring valuation. Reuters: Insmed discontinues development after mid-stage miss
• Negative Sentiment: Market reaction included a trading halt for INSM on the day the study results were released and follow-up headlines reporting the program freeze and stock drop, signaling outsized near-term volatility and negative investor sentiment. Investing.com: Stock falls after failed trial

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Truist Financial set a $205.00 target price on Insmed in a research report on Monday, January 12th. Roth Mkm raised Insmed to a "strong-buy" rating in a research report on Friday, January 23rd. Leerink Partners lifted their target price on Insmed from $210.00 to $215.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 24th. Jefferies Financial Group assumed coverage on Insmed in a research report on Monday, March 16th. They set a "buy" rating and a $228.00 target price on the stock. Finally, Citigroup reissued an "outperform" rating on shares of Insmed in a research report on Thursday, December 18th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Insmed has an average rating of "Buy" and a consensus target price of $212.67.

View Our Latest Stock Report on Insmed

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently added to or reduced their stakes in INSM. Norges Bank acquired a new stake in Insmed during the fourth quarter valued at approximately $506,625,000. Vanguard Group Inc. boosted its holdings in Insmed by 13.0% during the third quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company's stock valued at $2,870,957,000 after purchasing an additional 2,291,328 shares in the last quarter. RTW Investments LP boosted its holdings in Insmed by 57.0% during the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company's stock valued at $842,855,000 after purchasing an additional 1,758,321 shares in the last quarter. Artisan Partners Limited Partnership boosted its holdings in Insmed by 49.0% during the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company's stock valued at $711,076,000 after purchasing an additional 1,623,342 shares in the last quarter. Finally, Orbis Allan Gray Ltd acquired a new stake in Insmed during the second quarter valued at approximately $153,389,000.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Read More

• Five stocks we like better than Insmed

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].